tert-butyl 3-((1-(4-chloro-3-(3-chloro-5-cyanophenoxy)-2-(dimethoxymethyl)phenyl)-2-(diphenylmethylene)hydrazineyl)methyl)-1H-pyrazolo[3,4-b]pyridine-1-carboxylate | 1360621-11-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: tert-butyl 3-((1-(4-chloro-3-(3-chloro-5-cyanophenoxy)-2-(dimethoxymethyl)phenyl)-2-(diphenylmethylene)hydrazineyl)methyl)-1H-pyrazolo[3,4-b]pyridine-1-carboxylate
• CAS: 1360621-11-9
• 化学式: C₄₁H₃₆Cl₂N₆O₅
• 分子量: 763.68
• InChiKey: CPKSJUWXCVVHSR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.94
• 重原子数：
  54.0
• 可旋转键数：
  11.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  124.09
• 氢给体数：
  0.0
• 氢受体数：
  11.0

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-((1-(4-chloro-3-(3-chloro-5-cyanophenoxy)-2-(dimethoxymethyl)phenyl)-2-(diphenylmethylene)hydrazineyl)methyl)-1H-pyrazolo[3,4-b]pyridine-1-carboxylate 在 盐酸 作用下， 以 水 为溶剂， 反应 4.0h， 生成 3-chloro-5-{[5-chloro-1-(1H-pyrazolo[3,4-b]pyridin-3-ylmethyl)-1H-indazol-4-yl]oxy}benzonitrile
  参考文献：
  名称：

  Process Development and Large-Scale Synthesis of MK-6186, a Non-Nucleoside Reverse Transcriptase Inhibitor for the Treatment of HIV

  摘要：

  A new synthetic route has been developed to drug candidate 1, a second-generation NNRTI being developed as a potential treatment of HIV. Regiocontrol in a key alkylation step was achieved by selective N-alkylation of hydrazone 13. After a deprotection and cyclisation sequence, 1 was isolated in six steps in 35% overall yield from readily available starting materials.

  DOI：

  10.1021/op200334x
• 作为产物：
  描述：

  3-(3-bromo-6-chloro-2-formylphenoxy)-5-chlorobenzonitrile 在 tris-(dibenzylideneacetone)dipalladium(0) 、 caesium carbonate 、 对甲苯磺酸 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 2-甲基四氢呋喃 、 甲醇 、 水 为溶剂， 反应 20.92h， 生成 tert-butyl 3-((1-(4-chloro-3-(3-chloro-5-cyanophenoxy)-2-(dimethoxymethyl)phenyl)-2-(diphenylmethylene)hydrazineyl)methyl)-1H-pyrazolo[3,4-b]pyridine-1-carboxylate
  参考文献：
  名称：

  Process Development and Large-Scale Synthesis of MK-6186, a Non-Nucleoside Reverse Transcriptase Inhibitor for the Treatment of HIV

  摘要：

  A new synthetic route has been developed to drug candidate 1, a second-generation NNRTI being developed as a potential treatment of HIV. Regiocontrol in a key alkylation step was achieved by selective N-alkylation of hydrazone 13. After a deprotection and cyclisation sequence, 1 was isolated in six steps in 35% overall yield from readily available starting materials.

  DOI：

  10.1021/op200334x